Title
Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
Safety and Dose Finding Study of Oral MP470, a Multi-targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens
Phase
Phase 1Lead Sponsor
Astex Pharmaceuticals, Inc.Study Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Malignant DiseaseIntervention/Treatment
paclitaxel amuvatinib carboplatin topotecan docetaxel erlotinib etoposide ...Study Participants
101Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm.
Primary objective: Determine the MTD.
Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with specific SOC treatments.
Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
150 mg PO once daily at least 1 hour before or 2 hours after eating
Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
Inclusion Criteria: Malignant disease appropriate for initiating treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel, or erlotinib. Must be able to read, understand, and sign the IRB approved Informed Consent Form. At least 18 years old. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Adequate bone marrow function; normal renal and hepatic function, normal cardiac function. Exclusion Criteria: Any other active invasive malignancy except non-melanoma skin cancers or cervical carcinoma in situ. History of significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure and/or myocardial infarction. Received any anticancer agent(s) within the past 3 weeks, including investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic or hormonal therapy other than LHRH agonists. Received prior radiation therapy within the past 4 weeks. Any serious, uncontrolled active infection that requires systemic treatment or known infection with HIV, HCV or HBV. Patient requires treatment with immunosuppressive agents other than corticosteroids appropriate for the SOC chemotherapy regimen or those at stable doses for at least 2 weeks.
